CSL share price on watch as CEO announces retirement

Paul Perreault will be succeeded by Dr Paul McKenzie.

| More on:
A CSL scientist looking through a telescope in a lab

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • The CSL share price could be in for a big day after the company announced its CEO of 10 years will step down in the new year
  • Paul Perreault will retire from the top job in March and the company's chief operating officer Dr Paul McKenzie will take the reins
  • The CSL share price last traded at $298.20

The CSL Limited (ASX: CSL) share price is in focus amid news the company's long-term CEO and managing director will step down from the role.

Paul Perreault has been with the biotechnology icon for more than 25 years, 10 of which have been in the top job. He will be succeeded by Dr Paul McKenzie.

The CSL share price closed Monday's session trading at $298.20.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Let's take a closer look at the latest news from the S&P/ASX 200 Index (ASX: XJO) healthcare giant.

CSL announces Perreault's retirement and new CEO

The CSL share price could be one to watch on Tuesday after the company's CEO announced he plans to retire from the role and its board in March.

Perreault will continue to work as a strategic advisor for six months after handing over the reins, retiring in September next year.

Successor McKenzie currently serves as CSL's chief operating officer and will join the company's board immediately.

McKenzie has held leadership positions in the global biotechnology industry for more than 30 years. He has been with CSL since 2019, working to optimise the company's operations and grow the Seqirus, Plasma, and Vifor businesses.

Prior to joining the ASX 200 giant, McKenzie was executive vice president of pharmaceutical operations and technology at Biogen. He also previously held progressively senior-level roles at Johnson & Johnson, Bristol-Myers Squibb, and Merck.

Perreault commented on his retirement from the CEO position, saying:

Leading CSL during the last decade has been a privilege as we grew, innovated, and globalised to new levels – all while fostering a values-based culture focused on our promise to patients and public health around the world.

In working closely with Dr McKenzie for more than three years, I am confident he will continue to innovate and build on CSL's track record of growth for years to come.

Speaking on his appointment to the top job, McKenzie said:

I am excited, honoured and humbled for the opportunity to continue building CSL's legacy following the strong foundation established by Paul Perreault over the last decade.

We will continue focusing on executing our 2030 strategy, investing in innovation, and continue achieving sustainable and profitable growth.

CSL share price snapshot

The CSL share price has gone next to nowhere this year, gaining just 0.75% since the start of 2022. It's also 0.3% higher than it was this time last year.

Though, that's a better performance than the broader market.

The ASX 200 has fallen 5.4% year to date and 2.7% over the last 12 months.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Bristol-Myers Squibb, CSL, and Merck. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Biogen and Johnson & Johnson. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »